ArticleFrontiers in psychology2025
Somatization, psychological distress, and quality of life across fibromyalgia, irritable bowel syndrome, and their comorbid phenotype: a cross-sectional clinical comparison.
Article in Frontiers in psychology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibromyalgia (FM) and irritable bowel syndrome (IBS) are increasingly recognized as disorders involving central sensory processing and gut-brain axis dysregulation, often accompanied by autonomic and psychological disturbances. Methods: We investigated whether patients with comorbid FM and IBS (FM + IBS) experience greater somatization and reduced quality of life (QoL) compared to those with either condition alone, and if somatization serves as a predictor of gastrointestinal (GI) symptom severity. In this cross-sectional study, 53 adults (mean age 47.4 ± 1.3 years; 48 women) were classified into three groups: FM-only ( Results: FM-only and FM + IBS patients reported similar levels of pain, fatigue, and functional impact. GI symptoms were mild in FM-only patients but moderate in IBS-only and FM + IBS groups, with large effect sizes for psychological distress, mental health, and IBS severity. While FM + IBS participants showed slightly higher FM-related symptom scores, differences were not statistically significant. Somatization and diagnostic group independently predicted IBS severity, together explaining 50% of the variance. Conclusion: These findings demonstrate a progressive increase in somatization and a parallel decline in QoL across the spectrum from IBS-only to FM-only to FM + IBS, supporting the concept of functional somatic syndromes as a continuum. Incorporating routine assessment of somatization and QoL impairment may help identify patients at higher risk of treatment resistance and facilitate timely, integrated biopsychosocial strategies, including cognitive-behavioral and neuromodulatory interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.